tiprankstipranks
Trending News
More News >
CervoMed (CRVO)
NASDAQ:CRVO
US Market

CervoMed (CRVO) Stock Forecast & Price Target

Compare
1,172 Followers
See the Price Targets and Ratings of:

CRVO Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
CervoMed
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CRVO Stock 12 Month Forecast

Average Price Target

$22.75
▲(184.73% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for CervoMed in the last 3 months. The average price target is $22.75 with a high forecast of $27.00 and a low forecast of $19.00. The average price target represents a 184.73% change from the last price of $7.99.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","28":"$28","7.75":"$7.75","14.5":"$14.5","21.25":"$21.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$27.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.75,14.5,21.25,28],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.22,10.587692307692308,11.955384615384617,13.323076923076924,14.69076923076923,16.05846153846154,17.426153846153845,18.793846153846154,20.161538461538463,21.52923076923077,22.89692307692308,24.264615384615386,25.63230769230769,{"y":27,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.22,10.260769230769231,11.301538461538462,12.342307692307692,13.383076923076924,14.423846153846153,15.464615384615385,16.505384615384614,17.546153846153846,18.586923076923078,19.627692307692307,20.668461538461536,21.70923076923077,{"y":22.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.22,9.972307692307693,10.724615384615385,11.476923076923077,12.22923076923077,12.981538461538461,13.733846153846155,14.486153846153847,15.23846153846154,15.990769230769232,16.743076923076924,17.495384615384616,18.247692307692308,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.81,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.93,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.03,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.22,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$27.00Average Price Target$22.75Lowest Price Target$19.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CRVO
H.C. Wainwright
H.C. Wainwright
$25
Buy
212.89%
Upside
Reiterated
12/18/25
CervoMed Initiated With Buy Rating on Differentiated DLB Asset Neflamapimod and De-Risked Path to 2029 Launch
Cantor Fitzgerald Analyst forecast on CRVO
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Initiated
12/18/25
CervoMed initiated with an Overweight at Cantor FitzgeraldCervoMed initiated with an Overweight at Cantor Fitzgerald
JonesTrading Analyst forecast on CRVO
JonesTrading
JonesTrading
$20
Buy
150.31%
Upside
Reiterated
12/02/25
Optimistic Buy Rating for CervoMed Following Promising Phase 2b Trial Results and Strategic Insights
Roth MKM
$20$19
Buy
137.80%
Upside
Reiterated
11/11/25
CervoMed price target lowered to $19 from $20 at Roth CapitalCervoMed price target lowered to $19 from $20 at Roth Capital
Canaccord Genuity Analyst forecast on CRVO
Canaccord Genuity
Canaccord Genuity
$27
Buy
237.92%
Upside
Reiterated
11/11/25
Canaccord Genuity Sticks to Their Buy Rating for CervoMed (CRVO)
D. Boral Capital Analyst forecast on CRVO
D. Boral Capital
D. Boral Capital
$15$31
Buy
287.98%
Upside
Reiterated
08/18/25
CervoMed price target raised to $31 from $15 at D. Boral CapitalCervoMed price target raised to $31 from $15 at D. Boral Capital
Chardan Capital Analyst forecast on CRVO
Chardan Capital
Chardan Capital
$15
Buy
87.73%
Upside
Upgraded
05/12/25
Chardan Capital Markets reiterates Buy Rating on CervoMed (CRVO)Chardan Capital Markets analyst Danill Gataulin reiterated a Buy rating and $15.00 price target on CervoMed (NASDAQ: CRVO)
Brookline Capital Markets Analyst forecast on CRVO
Brookline Capital Markets
Brookline Capital Markets
$16$15
Buy
87.73%
Upside
Reiterated
03/17/25
CervoMed (CRVO) PT Lowered to $15 at Brookline Capital MarketsBrookline Capital Markets analyst Tyler Bussian lowered the price target on CervoMed (NASDAQ: CRVO) to $15.00 (from $16.00) while maintaining a Buy rating.
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CRVO
H.C. Wainwright
H.C. Wainwright
$25
Buy
212.89%
Upside
Reiterated
12/18/25
CervoMed Initiated With Buy Rating on Differentiated DLB Asset Neflamapimod and De-Risked Path to 2029 Launch
Cantor Fitzgerald Analyst forecast on CRVO
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Initiated
12/18/25
CervoMed initiated with an Overweight at Cantor FitzgeraldCervoMed initiated with an Overweight at Cantor Fitzgerald
JonesTrading Analyst forecast on CRVO
JonesTrading
JonesTrading
$20
Buy
150.31%
Upside
Reiterated
12/02/25
Optimistic Buy Rating for CervoMed Following Promising Phase 2b Trial Results and Strategic Insights
Roth MKM
$20$19
Buy
137.80%
Upside
Reiterated
11/11/25
CervoMed price target lowered to $19 from $20 at Roth CapitalCervoMed price target lowered to $19 from $20 at Roth Capital
Canaccord Genuity Analyst forecast on CRVO
Canaccord Genuity
Canaccord Genuity
$27
Buy
237.92%
Upside
Reiterated
11/11/25
Canaccord Genuity Sticks to Their Buy Rating for CervoMed (CRVO)
D. Boral Capital Analyst forecast on CRVO
D. Boral Capital
D. Boral Capital
$15$31
Buy
287.98%
Upside
Reiterated
08/18/25
CervoMed price target raised to $31 from $15 at D. Boral CapitalCervoMed price target raised to $31 from $15 at D. Boral Capital
Chardan Capital Analyst forecast on CRVO
Chardan Capital
Chardan Capital
$15
Buy
87.73%
Upside
Upgraded
05/12/25
Chardan Capital Markets reiterates Buy Rating on CervoMed (CRVO)Chardan Capital Markets analyst Danill Gataulin reiterated a Buy rating and $15.00 price target on CervoMed (NASDAQ: CRVO)
Brookline Capital Markets Analyst forecast on CRVO
Brookline Capital Markets
Brookline Capital Markets
$16$15
Buy
87.73%
Upside
Reiterated
03/17/25
CervoMed (CRVO) PT Lowered to $15 at Brookline Capital MarketsBrookline Capital Markets analyst Tyler Bussian lowered the price target on CervoMed (NASDAQ: CRVO) to $15.00 (from $16.00) while maintaining a Buy rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CervoMed

1 Month
xxx
Success Rate
4/7 ratings generated profit
57%
Average Return
+29.87%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +29.87% per trade.
3 Months
xxx
Success Rate
5/7 ratings generated profit
71%
Average Return
+66.53%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +66.53% per trade.
1 Year
Success Rate
4/7 ratings generated profit
57%
Average Return
+69.71%
reiterated a buy rating last month
Copying Boobalan Pachaiyappan's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +69.71% per trade.
2 Years
xxx
Success Rate
4/7 ratings generated profit
57%
Average Return
+68.69%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +68.69% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRVO Analyst Recommendation Trends

Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
13
8
10
12
13
Buy
0
0
0
0
0
Hold
0
1
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
9
11
13
13
In the current month, CRVO has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CRVO average Analyst price target in the past 3 months is 22.75.
Each month's total comprises the sum of three months' worth of ratings.

CRVO Financial Forecast

CRVO Earnings Forecast

The previous quarter’s earnings for CRVO were -$0.84.
The previous quarter’s earnings for CRVO were -$0.84.

CRVO Sales Forecast

The previous quarter’s earnings for CRVO were $322.57K.
The previous quarter’s earnings for CRVO were $322.57K.

CRVO Stock Forecast FAQ

What is CRVO’s average 12-month price target, according to analysts?
Based on analyst ratings, CervoMed’s 12-month average price target is 22.75.
    What is CRVO’s upside potential, based on the analysts’ average price target?
    CervoMed has 184.73% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CRVO a Buy, Sell or Hold?
          CervoMed has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is CervoMed’s price target?
            The average price target for CervoMed is 22.75. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $27.00 ,the lowest forecast is $19.00. The average price target represents 184.73% Increase from the current price of $7.99.
              What do analysts say about CervoMed?
              CervoMed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of CRVO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.